Nautilus Biotechnology, Inc. (NAUT), a company developing a single-molecule proteome analysis platform, reported its financial results for the first quarter ended March 31, 2026, highlighting progress toward commercialization and continued platform development.
The Seattle-based life sciences company also advanced its Early Access initiatives and strengthened its commercial leadership team during the quarter.
First Quarter 2026 Business Highlights
-Launched the Iterative Mapping Early Access Program, expanding access to its validated Tau proteoform assay, with Baylor College of Medicine as the first customer in an NIH-funded cancer study.
-Advanced processing and analysis of Tau proteome samples from collaborators, supporting platform validation and future scientific publications.
-Appointed Amber Faust as Vice President of Global Sales to lead Early Access expansion and drive adoption of the Voyager platform ahead of commercial launch.
-Continued development of a next-generation assay format aimed at improving probe compatibility, performance, and scalability.
CEO Sujal Patel said early customer engagement reinforced the value of the platform in real-world research settings and positioned the company to scale Early Access as it moves toward full commercial availability.
First Quarter 2026 Financial Results
-Operating expenses: $16.1 million, down 14% from $18.8 million in the prior-year period, driven by lower salaries, benefits, stock-based compensation, and facilities costs.
-Net loss: $14.7 million, compared to a net loss of $16.6 million a year earlier.
-Cash, cash equivalents and investments: $143.4 million as of March 31, 2026.
NAUT has traded between $0.62 and $4.31 over the past year. The stock is currently trading at $2.77, up 7.78%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.